The Right Molecules. Designed. Delivered.

Similar documents
Antibody Discovery at Evotec

Career Growth Areas in Physiology / Pharmacology

CONFLUENCE LIFE SCIENCES ACQUISITION

A full-service CRO with integrated early-stage capabilities

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Jefferies Global Health Care Conference. June 1, 2015

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

Optimisation de votre programme de développement

Introduction of Development Center for Biotechnology TAIWAN

Cancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development

Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline

SPEED UP YOUR TIME TO MARKET

MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT

A drug development crossroad lies ahead

Real World Drug Discovery A Chemist's Guide to Biotech and Pharmaceutical Research

Introduction to Drug Design and Discovery

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

CHAPTER 4. Milestones of the drug discovery

Explore the World of End-to-End. Integrated Lab Performance

PIONEERING WORLD-CLASS DRUG DISCOVERY IN AFRICA

Drug Metabolism & Pharmacokinetics. Bridging Chemistry, Biology, Pharmacology and Toxicology, from discovery to IND/NDA.

Specialty Lab Services. Deep science at scale

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase

to acquire Investor And Analyst Call Presentation January 4, 2008

21st Annual International Conference on Drug-Drug Interactions. Zach Mitts Northwest Account Manager

UNLEASH THE POWER OF PRECISION MEDICINE

Almac Overview.

Novartis Business Services HR University Relations. Chemical and Analytical Development. Early Talent Program

Metabolite ID. Introduction

SHANGHAI MEDICILON INC.

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

博奥信生物技术 ( 南京 ) 有限公司. Biosion (China) Recruiting

How Targets Are Chosen. Chris Wayman 12 th April 2012

Introduction to Drug Development in Commercializing Biomedical Technology

WuXi PharmaTech: Building an Open-Access Capability and Technology Platform. Jefferies Healthcare Conference November 2014

ND4BB Topic 3: Discovery and development of new drugs combatting Gram-negative infections

The Aptuit Center for Drug Discovery & Development Verona, Italy

So many science careers: find your own niche

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

QPS Neuropharmacology Overview

Assembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

BioDuro has had an exciting and eventful start to 2018 with acquisitions, partnership agreements, and significant R&D collaborations.

Micar Innovation. Drug Discovery Factory for novel drug molecules

Finding the right partner for preclinical into phase I. Facts, Threats & Opportunities

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

Drug Discovery and Development at NIH for Rare and Neglected Diseases September 29, 2009

NIAID Resources to Facilitate Medical Countermeasure Development

Stem Cell Research: Identifying emerging high priority policy issues

Background, Rationale & Discussion of vivopharm Acquisition

Quo vadis Drug Discovery

NIH-RAID: A ROADMAP Program

Preclinical Development of Microbicides How the Most Promising Products Advance to Clinical Trial Evaluation

4/10/2017. Agenda. Overview: Biomarker Industry. + Industry Overview + Biomarker Labs Overview + Biomarker Intended Use and Challenges

Innovative Medicines Initiative

DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION

PPD LABORATORIES COMPREHENSIVE SERVICES

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development

Financial Results FY2018 Q3

Biotech Showcase 2016


Successful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium

Anti-cancer drug discovery: from bench to bedside

Key Activities. Ofer Reizes, Ph.D. Skills Development Director

Agreed with W. Cornell Graduate Program and Tri-I

EOS: a Focussed Oncology Company Overview Forum della Ricerca e dell Innovazione Padova, May 16, 2008

Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

Tuberculosis Drug Accelerator

Personalized CAR-T Immunotherapy Platform

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

In Vitro Pharmacology Services

Chemoinformatic Tools for the Hit Discovery Process

The Pharmaceutical Technology Specialists.

LAB EXPERTS AT YOUR SIDE Over twenty years of experience

Genomics-Enabled Drug Repurposing and Repositioning: A Workshop:

Translational Research through Public-Private Partnerships. 65 th Annual Bohan Lecture. Scott J. Weir, PharmD, PhD 08 October 2011

EARLY PHASE DEVELOPMENT SOLUTIONS

Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities

Dennis Wright, Ph.D. Professor of Medicinal Chemistry NPDD Initiative UCONN School of Pharmacy University of Connecticut

From Bench to Bedside. Russ H. Read June 23, 2014

Development of a new medicinal product. as. MUDr. Martin Votava, PhD.

Defining the Expertise for the 21 st Century Neuroscience Workforce. James E. Barrett, Ph.D. Professor and Chair

A Machine-Learning Drug Design Platform Company BUSINESS OVERVIEW

Company Report Daring to be different

PlantForm Corporation

CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE DMPK OVERVIEW XENOGRAFT MODELS ADME SUMMARY REPORT.

REIMAGINING DRUG DEVELOPMENT:

NIH Blueprint for Neurotherapeutics: A novel approach to early stage drug discovery research funding

How to Manage Metabolite Profiling Requests, the CRO Perspective. Dr Martha A Green Manager Qualitative Mass Spectrometry Charles River, Edinburgh

Competing & Collaborating to Achieve Successful Drug Repositioning

Technology Development Funding Program Round 3

The Need for Scientific. Data Annotation. Alick K Law, Ph.D., M.B.A. Marketing Manager IBM Life Sciences.

Jefferies Healthcare Conference June 8, Protein Engineering. Transform Your Thinking

Fast Track Drug Development The Clinical (Caleidoscopic) Perspective

Services for Medical Devices. Expert solutions for product development from concept to commercialization

Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program

What IMI means for POLAND

Bio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies

Transcription:

The Right Molecules. Designed. Delivered.

400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered Phase II Clinical Trials 1 Entered Phase III Clinical Trials (Breakthrough Designation) IDSU by WuXi 01

IDSU by WuXi. Where Expertise Means Everything. The International Discovery Service Unit (IDSU) is WuXi s solution to address our industry s drug discovery challenges through expertise in medicinal chemistry and program management. We collaborate closely with our international customers ranging from pharma and biotech to academia to rapidly advance programs towards key inflection points and milestones by leveraging IDSU s peer-recognized expertise and WuXi s integrated platform from hit identification to preclinical candidate selection and beyond. With some of the industry s finest and most experienced medicinal chemists at WuXi, we aspire to become the partner-of-choice in externalized solutions to enable advancement of programs in ways that are both smarter and faster. Collaborative. Having delivered over 20 preclinical candidates since 2008 for our partners, we understand the unique challenges and needs of each program. We work closely with partners to establish strategy, customize resources and guide project execution to deliver on goals. WuXi s China Platform Execution of: HTS & Chemistry in vitro & in vivo Biology DMPK & Formulation Safety Assessment WuXi s IDSU Team Medicinal Chemistry Project Execution Program Management Partner Disease Biology Target of Interest Inhouse Expertise Efficient. We provide our customers with access to WuXi s best-in-class fully integrated drug discovery and development platform to seamlessly progress programs from target through to preclinical candidate selection and beyond. Protein crystallography FBDD and SBDD Modeling and Chemoinformatics Structural Biology and Computational >300 Employees Non-GLP and GLP Toxicokinetics and bioanalytical Safety Assessment and Toxicology Synthetic Chemistry Medicinal Chemistry 2200+ Chemists Discovery to GMP Radiolabel Chemistry ADME and DMPK in vitro Biology & in vivo Pharmacology > 350 Scientists Rodents to NHPs Discovery to IND-enabling Metabolite ID Radiolabeled Studies > 350 Scientists Multiple biology screening platforms Electrophysiology HTS and compound collection Translational models Genomics Center (CLIA-certified) Biomarkers IDSU by WuXi 02

Meet the Team that Has Made Difference to Patients Global Expertise Local Connectivity Small molecule drug discovery requires a deep understanding of biological context coupled to knowledge and experience of medicinal chemistry to make the right molecules to answer the right questions. WuXi has a powerful core of experienced, industry-seasoned drug hunters who are peer recognized including induction to the American Chemical Society Hall of Fame and recognition as Heroes of Chemistry by The American Chemical Society. Collectively, IDSU members have been named as inventors and authors on >750 patents and publications, and have made significant contributions to discovery projects throughout their careers, including blockbuster drugs that are profoundly improving patients lives. IDSU s highly experienced medicinal chemists are located in key biopharma clusters of the United States and Europe. These highly accomplished and industry-seasoned drug hunters function as a local resource to our valued partners. WuXi s local presence offers a range of advantages in program management, strategic planning in projects of the collaboration, and streamlining of communications with WuXi s China-based operations and execution teams. IDSU by WuXi 03

Richard Soll, PhD SVP and Head of IDSU 30+ years in drug discovery; former CSO and Head of R&D at TargeGen; 130+ patents and publications Joe Vacca, PhD SVP of IDSU and Head of ESSP 30+ years at Merck; Honoree of ACS Hall of Fame and Heroes of Chemistry ; 100+ patents and publications Linus Lin, PhD VP of IDSU and VP of Operations & Chemistry 20+ years in drug discovery; 60+ patents and publications Tao Guo, PhD VP of Medicinal Chemistry 20+ years in drug discovery; 80 patents and publications John Wai. PhD VP of Medicinal Chemistry 24 yrs at Merck; Isentress ; Honoree of ACS "Heroes of Chemistry" Craig Coburn. PhD VP of Medicinal Chemistry 20 yrs at Merck; multiple candidates including Elbasvir (breakthrough HCV drug) IDSU by WuXi 04

Medchem Case Studies Osteoporosis OBJECTIVE: Discover a novel PCC candidate with better efficacy, PK and safety profiles than a competitor compound 17 months MILESTONE From patent literature to First PCC Nomination within 17 months Pain OBJECTIVE: Discover a novel PCC candidate with better efficacy, PK and safety profiles than a benchmark compound 24 MILESTONE From patent literature to First PCC months Nomination within 24 months Antiviral OBJECTIVE: Discover the best-in-class compound with improved PK profiles 2 PCCs MILESTONE Discovered 2 PCCs 1 st PCC went to Phase I 2 nd PCC advanced to Phase III CV/MED OBJECTIVE: Discover a novel PCC with better potency, PK, and safety profiles than a competitor s compounds 20 months MILESTONE Discovered a novel PCC within 20 months IDSU by WuXi 05

Enabling Platform We understand that each partner has different needs and internal capabilities. Working with IDSU enables our partners to access WuXi s industry-leading capability and technology platform in efficient and cost-effective ways. Our small molecule platform spans the entire R&D value chain from discovery to commercialization. Our laboratory services extend from in-depth discovery chemistry and biology to preclinical development including GLP toxicology and bioanalytical. Development and manufacturing services range from formulation and analytical R&D to GMP clinical drug product and commercial API manufacturing at our STA subsidiary. WuXi s Genome Center tackles challenges in personalized medicine, while clinical and regulatory services support our partners needs to conduct the highest-quality clinical trials in China for Chinese and international regulatory filings. IDSU by WuXi 06

International Discovery Service Unit The Right Molecules. Designed. Delivered. www.wuxiapptec.com/idsu Contact Us IDSU Leadership Rich Soll richard_soll@wuxiapptec.com Joe Vacca joe.vacca@wuxiapptec.com Linus Lin linus_lin@wuxiapptec.com Tao Guo guo_tao@wuxiapptec.com IDSU Business Development Declan Ryan declan.ryan@wuxiapptec.com US West Coast: Jennifer Milanovich jennifer.milanovich@wuxiapptec.com US East Coast: Linda Zhao linda.zhao@wuxiapptec.com Europe: Rosie Hutchings rosie.hutchings@wuxiapptec.com